NR2D-containing NMDA receptors mediate tissue plasminogen activator-promoted neuronal excitotoxicity

Cell Death and Differentiation

Volumn 17, Issue 5, 2010, Pages 860-871

  Baron, A ^a,b   Montagne, A ^a,b   Casse F ^a,b   Launay, S ^a,b   Maubert, E ^a,b   Ali, C ^a,b   Vivien, D ^a,b  

^a UNIVERSITÉ DE CAEN   (France)

^b CNRS   (France)

Author keywords

Excitotoxicity; NMDA; NR2D; Pre conditionning; TPA

Indexed keywords

1 (PHENANTHRENE 2 CARBONYL)PIPERAZINE 2,3 DICARBOXYLIC ACID; N METHYL DEXTRO ASPARTIC ACID RECEPTOR; N METHYL DEXTRO ASPARTIC ACID RECEPTOR 2D; PHENANTHRENE DERIVATIVE; TISSUE PLASMINOGEN ACTIVATOR; UNCLASSIFIED DRUG;

ANIMAL CELL; ANIMAL TISSUE; ARTICLE; BRAIN NERVE CELL; CONTROLLED STUDY; EXCITOTOXICITY; FETUS; HIPPOCAMPUS; HISTOLOGY; IMMUNOBLOTTING; IMMUNOCYTOCHEMISTRY; IMMUNOHISTOCHEMISTRY; IN VITRO STUDY; IN VIVO STUDY; MOUSE; NERVE CELL CULTURE; NEUROTOXICITY; NONHUMAN; PRIORITY JOURNAL; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; RNA INTERFERENCE; SIGNAL TRANSDUCTION; SYNAPSE;

ANIMALS; CELLS, CULTURED; DIAZONIUM COMPOUNDS; FIBRINOLYTIC AGENTS; IMMUNOBLOTTING; IMMUNOHISTOCHEMISTRY; MICE; NEURONS; POTASSIUM CHLORIDE; PYRIDINES; RECEPTORS, N-METHYL-D-ASPARTATE; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION; RNA INTERFERENCE; TISSUE PLASMINOGEN ACTIVATOR;

EID: 77950860159     PISSN: 13509047     EISSN: 14765403     Source Type: Journal    
DOI: 10.1038/cdd.2009.172     Document Type: Article

References (40)

1. Baranes D, Lederfein D, Huang YY, Chen M, Bailey CH, Kandel ER. Tissue plasminogen activator contributes to the late phase of LTP and to synaptic growth in the hippocampal mossy fiber pathway. Neuron 1998; 21: 813-825. (Pubitemid 28498789)
2. Pang PT, Teng HK, Zaitsev E, Woo NT, Sakata K, Zhen S et al. Cleavage of proBDNF by tPA/plasmin is essential for long-term hippocampal plasticity. Science 2004; 306: 487-491. (Pubitemid 39372449)
3. Bruno MA, Cuello AC. Activity-dependent release of precursor nerve growth factor, conversion to mature nerve growth factor, and its degradation by a protease cascade. Proc Natl Acad Sci USA 2006; 103: 6735-6740.
4. Yepes M, Roussel BD, Ali C, Vivien D. Tissue-type plasminogen activator in the ischemic brain: more than a thrombolytic. Trends Neurosci 2009; 32: 48-55.
5. Benchenane K, Berezowski V, Ali C, Fernández-Monreal M, López-Atalaya JP, Brillault J et al. Tissue-type plasminogen activator crosses the intact blood-brain barrier by l ow-density lipoprotein receptor-related protein-mediated transcytosis. Circulation 2005; 111: 2241-2249. (Pubitemid 40632441)
6. Martin AM, Kuhlmann C, Trossbach S, Jaeger S, Waldron E, Roebroek A et al. The functional role of the second NPXY motif of the LRP1 beta-chain in tissue-type plasminogen activator-mediated activation of N-methyl-D-aspartate receptors. J Biol Chem 2008; 283: 12004-12013.
7. Samson AL, Nevin ST, Croucher D, Niego B, Daniel PB, Weiss TW et al. Tissue-type plasminogen activator requires a co-receptor to enhance NMDA receptor function. J Neurochem 2008; 107: 1091-1101.
8. Polavarapu R, Gongora MC, Yi H, Ranganthan S, Lawrence DA, Strickland D et al. Tissuetype plasminogen activator-mediated shedding of astrocytic low-density lipoprotein receptor-related protein increases the permeability of the neurovascular unit. Blood 2007; 109: 3270-3278. (Pubitemid 46572512)
9. Lee HY, Hwang IY, Im H, Koh JY, Kim YH. Non-proteolytic neurotrophic effects of tissue plasminogen activator on cultured mouse cerebrocortical neurons. J Neurochem 2007; 101: 1236-1247. (Pubitemid 46718808)
10. Nicole O, Docagne F, Ali C, Margaill I, Carmeliet P, MacKenzie ET et al. The proteolytic activity of tissue-plasminogen activator enhances NMDA receptor-mediated signaling. Nat Med 2001; 7: 59-64. (Pubitemid 32095643)
11. Fernández-Monreal M, López-Atalaya JP, Benchenane K, Cacquevel M, Dulin F, Le Caer JP et al. Arginine 260 of the amino-terminal domain of NR1 subunit is critical for tissue-type plasminogen activator-mediated enhancement of N-methyl-D-aspartate receptor signaling. J Biol Chem 2004; 279: 50850-50856. (Pubitemid 40017823)
12. Benchenane K, Castel H, Boulouard M, Bluthé R, Fernandez-Monreal M, Roussel BD et al. Anti-NR1 N-terminal-domain vaccination unmasks the crucial action of tPA on NMDAreceptor- mediated toxicity and spatial memory. J Cell Sci 2007; 120: 578-585. (Pubitemid 46437892)
13. Pawlak R, Melchor JP, Matys T, Skrzypiec AE, Strickland S. Ethanol-withdrawal seizures are controlled by tissue plasminogen activator via modulation of NR2B-containing NMDA receptors. Proc Natl Acad Sci USA 2005; 102: 443-448. (Pubitemid 40116786)
14. Norris EH, Strickland S. Modulation of NR2B-regulated contextual fear in the hippocampus by the tissue plasminogen activator system. Proc Natl Acad Sci USA 2007; 104: 13473-13478. (Pubitemid 47293969)
15. Medina MG, Ledesma MD, Domínguez JE, Medina M, Zafra D, Alameda F et al. Tissue plasminogen activator mediates amyloid-induced neurotoxicity via Erk1/2 activation. EMBO J 2005; 24: 1706-1716. (Pubitemid 40704981)
16. Samson AL, Medcalf RL. Tissue-type plasminogen activator: a multifaceted modulator of neurotransmission and synaptic plasticity. Neuron 2006; 50: 673-678.
17. Thomas GM, Huganir RL. MAPK cascade signalling and synaptic plasticity. Nat Rev Neurosci 2004; 5: 173-183.
18. Gardoni F, Di Luca M. New targets for pharmacological intervention in the glutamatergic synapse. Eur J Pharmacol 2006; 545: 2-10. (Pubitemid 44215874)
19. Lau CG, Zukin RS. NMDA receptor trafficking in synaptic plasticity and neuropsychiatric disorders. Nat Rev Neurosci 2007; 8: 413-426. (Pubitemid 46789232)
20. Cull-Candy SG, Leszkiewicz DN. Role of distinct NMDA receptor subtypes at central synapses. Sci STKE 2004; 2004: re16.
21. Papadia S, Hardingham GE. The dichotomy of NMDA receptor signaling. Neuroscientist 2007; 13: 572-579. (Pubitemid 350077306)
22. Kohr G. NMDA receptor function: subunit composition versus spatial distribution. Cell Tissue Res 2006; 326: 439-446. (Pubitemid 44435819)
23. Feng B, Tse HW, Skifter DA, Morley R, Jane DE, Monaghan DT. Structure-activity analysis of a novel NR2C/NR2D-preferring NMDA receptor antagonist: 1-(phenanthrene-2- carbonyl) piperazine-2,3-dicarboxylic acid. Br J Pharmacol 2004; 141: 508-516. (Pubitemid 38297013)
24. Harney SC, Jane DE, Anwyl R. Extrasynaptic NR2D-containing NMDARs are recruited to the synapse during LTP of NMDAR-EPSCs. J Neurosci 2008; 28: 11685-11694.
25. Soriano FX, Papadia S, Hofmann F, Hardingham NR, Bading H, Hardingham GE. Preconditioning doses of NMDA promote neuroprotection by enhancing neuronal excitability. J Neurosci 2006; 26: 4509-4518. (Pubitemid 44315350)
26. Hardingham GE, Fukunaga Y, Bading H. Extrasynaptic NMDARs oppose synaptic NMDARs by triggering CREB shut-off and cell death pathways. Nat Neurosci 2002; 5: 405-414, Comment in: Nat Neurosci 2002; 5: 389-390. (Pubitemid 34454245)
27. Liu Y, Wong TP, Aarts M, Rooyakkers A, Liu L, Lai TW et al. NMDA receptor subunits have differential roles in mediating excitotoxic neuronal death both in vitro and in vivo. J Neurosci 2007; 27: 2846-2857. (Pubitemid 46438991)
28. Al-Hallaq RA, Conrads TP, Veenstra TD, Wenthold RJ. NMDA di-heteromeric receptor populations and associated proteins in rat hippocampus. J Neurosci 2007; 27: 8334-8343.
29. Hrabetova S, Serrano P, Blace N, Tse HW, Skifter DA, Jane DE et al. Distinct NMDA receptor subpopulations contribute to long-term potentiation and long-term depression induction. J Neurosci 2000; 20: RC81.
30. Wenzel A, Fritschy JM, Mohler H, Benke D. NMDA receptor heterogeneity during postnatal development of the rat brain: differential expression of the NR2A, NR2B, and NR2C subunit proteins. J Neurochem 1997; 68: 469-478. (Pubitemid 27044705)
31. Brickley SG, Misra C, Mok MH, Mishina M, Cull-Candy SG. NR2B and NR2D subunits coassemble in cerebellar Golgi cells to form a distinct NMDA receptor subtype restricted to extrasynaptic sites. J Neurosci 2003; 23: 4958-4966. (Pubitemid 36793222)
32. Pang PT, Teng HK, Zaitsev E, Woo NT, Sakata K, Zhen S et al. Cleavage of proBDNF by tPA/plasmin is essential for long-term hippocampal plasticity. Science 2004; 306: 487-491. (Pubitemid 39372449)
33. Zhang J, Qian H, Zhao P, Hong SS, Xia Y. Rapid hypoxia preconditioning protects cortical neurons from glutamate toxicity through delta-opioid receptor. Stroke 2006; 37: 1094-1099.
34. Tauskela JS, Fang H, Hewitt M, Brunette E, Ahuja T, Thiverge JP et al. Elevated synaptic activity preconditions neurons against an in vitro model of ischemia. J Biol Chem 2008; 283: 34667-34676.
35. Yan GM, Ni B, Weller M, Wood KA, Paul SM. Depolarization or glutamate receptor activation blocks apoptotic cell death of cultured cerebellar granule neurons. Brain Res 1994; 656: 43-51. (Pubitemid 24263028)
36. Marini AM, Paul SM. N-methyl-D-aspartate receptor-mediated neuroprotection in cerebellar granule cells requires new RNA and protein synthesis. Proc Natl Acad Sci USA 1992; 89: 6555-6559.
37. Papadia S, Stevenson P, Hardingham NR, Bading H, Hardingham GE. Nuclear Ca2+ and the cAMP response element-binding protein family mediate a late phase of activitydependent neuroprotection. J Neurosci 2005; 25: 4279-4287. (Pubitemid 40628772)
38. Terro F, Esclaire F, Yardin C, Hugon J. N-methyl-D-aspartate receptor blockade enhances neuronal apoptosis induced by serum deprivation. Neurosci Lett 2000; 278: 149-152. (Pubitemid 30009479)
39. Liot G, Roussel BD, Lebeurrier N, Benchenane K, López-Atalaya JP, Vivien D et al. Tissue-type plasminogen activator rescues neurones from serum deprivation-induced apoptosis through a mechanism independent of its proteolytic activity. J Neurochem 2006; 98: 1458-1464. (Pubitemid 44200437)
40. Rose K, Goldberg MP, Choi DW. Cytotoxicity in murine cortical cell culture In: Tyson CA, Frazier JM (eds). In Vitro Biological Methods. Academic Press: San Diego, California, USA, 1993.